William Blair & Company
ALLO icon

William Blair & Company’s Allogene Therapeutics ALLO Stock Holding History

William Blair & Company’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,040
Closed -$73.3K – 2002
2026
Q1 		$73.3K Buy
+30,040
New +$60.2K ﹤0.01% 1644

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

William Blair & Company's ALLO Position: Q2 2026 in Review

William Blair & Company sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 30,040 shares — an estimated $73.3K sold.

William Blair & Company first reported a position in ALLO in Q1 2026 and held it in 1 quarter. The position peaked at $73.3K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • William Blair & Company reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • William Blair & Company sold 30,040 Allogene Therapeutics shares in Q2 2026, an estimated $73.3K.
  • William Blair & Company first reported a position in Allogene Therapeutics in Q1 2026 and held it in 1 quarter.
  • William Blair & Company's Allogene Therapeutics position peaked at $73.3K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.